GTx To Report Top Line Results From Enobosarm POWER Trials - Quick Facts

(RTTNews) - GTx Inc. (GTXI) announced that top line results from the two Phase 3 trials, POWER1 and POWER2, on the effects of enobosarm for the prevention and treatment of muscle wasting in non-small cell lung cancer patients will be presented on September 28, 2013, at the European Cancer Congress 2013 in Amsterdam.

The POWER trials were designed to assess the response rates of enobosarm versus placebo for the co-primary endpoints at 3 months of treatment on maintenance or improvement of total lean body mass assessed by Dual-energy X-ray Absorptiometry and improvement in physical function measured by the stair climb test.